Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial (https://www.myeloma.org/imwg/mechanisms-peripheral-neuropathy-bortezomib-vincristine)
This analysis focuses on comparing both early onset and late onset bortezomib-induced peripheral neuropathy to vincristine-induced peripheral neuropathy. When a myeloma patient has dose-limiting based toxicity due to bortezomib, bortezomib-induced peripheral neuropathy may result, negatively impacting a patient.
Authors:
Broyl A, Corthals SL, Jongen JL, van der Holt B, Kuiper R, de Knegt Y, van Duin M, el Jarari L, Bertsch U, Lokhorst HM, Durie BG, Goldschmidt H, Sonneveld P
Click here to view article: